상기도 감염 치료 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the upper respiratory tract infection treatment market size is projected to be USD 45.94 billion in 2025, USD 49.36 billion in 2026, and reach USD 70.90 billion by 2031, growing at a CAGR of 7.51% from 2026 to 2031.

This report is Segmented by Infection Type (Bacterial Infections, and More), Treatment Type (Antibiotics, and More), Route of Administration (Oral, and More), Age Group (Pediatric, and More), Distribution Channel (Retail Pharmacies, and More), Indication (Common Cold, and More), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Upper Respiratory Tract Infection Treatment Market Trends and Insights

Rising Burden of Viral Upper Respiratory Infections

South-East Asia and sub-Saharan Africa recorded the highest incidence rates in the recent past. These regions provide a large base of treatment need as more consumers use formal pharmacy channels. Rhinoviruses cause an estimated 50% of cold-related upper respiratory infections, yet no licensed antiviral specifically targets them. The upper respiratory tract infection treatment market has a clear gap where companies can develop treatments for this common cause of illness. The circulation of RSV, influenza, and COVID-19 alongside rhinoviruses can extend demand for symptom management beyond the traditional winter period.

OTC Self-Care Expansion for Symptom Relief

The upper respiratory tract infection treatment market benefits consumers can identify routine symptoms and obtain suitable relief without a physician visit. Digital symptom checkers and at-home tests have shortened the path between symptom onset and product purchase. These tools can help consumers decide when self-care is suitable and when clinical assessment is needed. Combination products that include decongestants, antihistamines, and analgesics remain relevant for people seeking relief from several symptoms. Manufacturers can use clearer labels and age-appropriate formats to support informed purchase decisions. The upper respiratory tract infection treatment market also gains from wider retail availability, although OTC products must remain aligned with clinical guidance and safety requirements.

Antibiotic Resistance and Stewardship Constraints

Antibiotic resistance limits the role of broad-spectrum antibiotics in the treatment of upper respiratory tract infections. The World Health Organization reported that 1 in 6 laboratory-confirmed bacterial infections globally in 2023-2024 were resistant to first-line antibiotics. The rate reached 1 in 3 infections in the WHO South-East Asia and Eastern Mediterranean Regions. This limits the clinical utility of antibiotics in regions with substantial infection burden and growing prescription use. It also increases the need for careful diagnosis and for non-antibiotic options where they are clinically appropriate. The upper respiratory tract infection treatment market must respond with therapies that improve symptom care while supporting responsible antimicrobial use.

Other drivers and restraints analyzed in the detailed report include:

1. Stewardship Shift Away from Unnecessary Antibiotic Use
2. Faster Reformulation Cycles for Nonprescription Cold and Flu Products
3. Self-Limiting Disease Nature Limits Premium Rx Uptake

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Viral infections held 51.81% of the upper respiratory tract infection treatment market in 2025 and are forecast to grow at 8.62% CAGR through 2031. Their position reflects the high frequency of rhinovirus, RSV, and influenza infections. The upper respiratory tract infection treatment market size for viral infections is supported by demand for symptom relief as well as antiviral development. Bacterial infections remain important because antibiotics are used for conditions such as bacterial sinusitis and streptococcal pharyngitis. Fungal infections are smaller and serve a more specialized clinical need.

No licensed therapy specifically targets rhinovirus despite its role in an estimated 50% of common colds. This gap gives antiviral developers a defined area for research and development. Viral treatment approaches must also respond to overlapping respiratory virus seasons. Infections may be clinically similar at the onset, which makes an appropriate diagnosis important before treatment selection. Companies that develop therapies for well-defined viral indications can compete on medical need rather than only on established product categories. The upper respiratory tract infection treatment market remains dependent on antiviral progress, diagnostic clarity, and access to symptomatic care.

Antibiotics held 30.90% of revenue in 2025. Antibiotics retain a substantial role in bacterial sinusitis, streptococcal pharyngitis, and mixed-etiology protocols. Their use is also subject to stewardship programs that discourage treatment where infection is likely viral. NSAIDs are forecast to grow at 9.59% CAGR through 2031. NSAIDs address fever and inflammation and are gaining attention as an initial response for viral upper respiratory tract infections. Antivirals, antihistamines, cough suppressants, expectorants, and decongestants address different symptoms and care requirements. This range of treatments allows the upper respiratory tract infection treatment market to serve varied episodes and patient needs.

A Phase 3 trial published in 2025 found that pelubiprofen was non-inferior to loxoprofen for fever reduction in acute upper respiratory tract infections. The trial reported a comparable safety profile for the 2 treatments. These results support further work on NSAID formulations that offer a rapid onset. Treatment makers must also distinguish products by indication, safety profile, and patient age. Antibiotic developers retain opportunities when bacterial disease is clearly identified. The upper respiratory tract infection treatment industry is therefore moving toward a treatment mix that places more weight on responsible symptomatic care.

Complete Report Scope:

• By Infection Type
  • Bacterial Infections
  • Viral Infections
  • Fungal Infections
• By Treatment Type
  • Antibiotics
  • Antivirals
  • Antifungals
  • Decongestants
  • Expectorants
  • Antihistamines
  • Cough Suppressants
  • NSAIDs
• By Route of Administration
  • Oral
  • Intravenous
  • Inhalation
  • Topical
• By Age Group
  • Pediatric
  • Adult
  • Geriatric
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• By Indication
  • Common Cold
  • Sinusitis
  • Pharyngitis
  • Laryngitis
  • Other Indications
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.70% of revenue in 2025, the largest regional share in the upper respiratory tract infection treatment market. The region has high OTC use, established retail pharmacy networks, and broad access to branded and generic treatments. Telehealth adoption can also support the assessment of routine respiratory symptoms. Stewardship efforts are changing treatment selection and reducing avoidable antibiotic use. This creates room for symptom relief products and antivirals when clinically appropriate.

Europe has a varied prescription environment because reimbursement and OTC rules differ across national markets. Germany has a strong generic medicine base, while France has meaningful spending on OTC cold remedies. The United Kingdom's NHS stewardship programs also shape prescribing behavior. GSK's European application to expand Arexvy to adults aged 18 years and older was accepted by the EMA in June 2025. The upper respiratory tract infection treatment market size in Europe is influenced by mature pharmacy access and continuing oversight of product safety.

Asia-Pacific is forecast to grow at 11.26% CAGR through 2031, the fastest regional rate. This expansion reflects population scale, higher access to formal pharmaceutical channels, and a mix of local and multinational suppliers. India's manufacturers, including Cipla, Sun Pharma, and Dr. Reddy's, serve price-sensitive demand with respiratory generics. Pediatric guidelines in China and the UAE also show the wider regional importance of standardized care pathways. The Middle East and Africa grow from a smaller base, with GCC pediatric guidance and South African private and public demand supporting activity. South America is supported by Brazil and Argentina, though currency volatility and healthcare spending constraints limit near-term adoption of premium products.

1. Abbott Laboratories
2. Abbvie
3. Alcon
4. AstraZeneca
5. Bayer
6. Boehringer Ingelheim
7. Chiesi Farmaceutici
8. Cipla
9. Dr. Reddy's Laboratories Ltd.
10. GlaxoSmithKline
11. Johnson & Johnson
12. Merck
13. Mylan
14. Novartis
15. Pfizer
16. Roche
17. Sanofi
18. Sun Pharmaceuticals Industries
19. Teva Pharmaceutical Industries
20. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Viral Upper Respiratory Infections
  • 4.2.2 OTC Self-Care Expansion for Symptom Relief
  • 4.2.3 Stewardship Shift Away from Unnecessary Antibiotic Use
  • 4.2.4 Faster Reformulation Cycles for Nonprescription Cold and Flu Products
  • 4.2.5 Telemedicine-Linked Prescribing for Seasonal URI Episodes
  • 4.2.6 Pediatric Care Standardization in School-Age Respiratory Outbreaks
• 4.3 Market Restraints
  • 4.3.1 Antibiotic Resistance and Stewardship Constraints
  • 4.3.2 Weak Efficacy Perception for Some OTC Decongestants
  • 4.3.3 Self-Limiting Disease Nature Limits Premium Rx Uptake
  • 4.3.4 Regulatory Scrutiny on Ingredient Safety and Label Claims
• 4.4 Value-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Infection Type
  • 5.1.1 Bacterial Infections
  • 5.1.2 Viral Infections
  • 5.1.3 Fungal Infections
• 5.2 By Treatment Type
  • 5.2.1 Antibiotics
  • 5.2.2 Antivirals
  • 5.2.3 Antifungals
  • 5.2.4 Decongestants
  • 5.2.5 Expectorants
  • 5.2.6 Antihistamines
  • 5.2.7 Cough Suppressants
  • 5.2.8 NSAIDs
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Intravenous
  • 5.3.3 Inhalation
  • 5.3.4 Topical
• 5.4 By Age Group
  • 5.4.1 Pediatric
  • 5.4.2 Adult
  • 5.4.3 Geriatric
• 5.5 By Distribution Channel
  • 5.5.1 Retail Pharmacies
  • 5.5.2 Hospital Pharmacies
  • 5.5.3 Online Pharmacies
• 5.6 By Indication
  • 5.6.1 Common Cold
  • 5.6.2 Sinusitis
  • 5.6.3 Pharyngitis
  • 5.6.4 Laryngitis
  • 5.6.5 Other Indications
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Abbott Laboratories
  • 6.3.2 AbbVie Inc.
  • 6.3.3 Alcon Inc.
  • 6.3.4 AstraZeneca plc
  • 6.3.5 Bayer AG
  • 6.3.6 Boehringer Ingelheim International GmbH
  • 6.3.7 Chiesi Farmaceutici S.p.A.
  • 6.3.8 Cipla Limited
  • 6.3.9 Dr. Reddy's Laboratories Ltd.
  • 6.3.10 GlaxoSmithKline plc
  • 6.3.11 Johnson and Johnson
  • 6.3.12 Merck and Co., Inc.
  • 6.3.13 Mylan N.V.
  • 6.3.14 Novartis AG
  • 6.3.15 Pfizer Inc.
  • 6.3.16 Roche Holding AG
  • 6.3.17 Sanofi
  • 6.3.18 Sun Pharmaceutical Industries Ltd.
  • 6.3.19 Teva Pharmaceutical Industries Ltd.
  • 6.3.20 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment